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Edited by Robert BaroukiAbstract Aquaporins are channels that allow the movement of
water across the cell membrane. Some members of the aquaporin
family, the aquaglyceroporins, also allow the transport of gly-
cerol, which is involved in the biosynthesis of triglycerides and
the maintenance of fasting glucose levels. Aquaporin-7 (AQP7)
is a glycerol channel mainly expressed in adipocytes. The dele-
tion of AQP7 gene in mice leads to obesity and type 2 diabetes.
AQP7 modulates adipocyte glycerol permeability thereby con-
trolling triglyceride accumulation and fat cell size. Furthermore,
the coordinated regulation of fat-speciﬁc AQP7 and liver-
speciﬁc AQP9 may be key to determine glucose metabolism in
insulin resistance.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Diabetes1. Aquaporin-7
Aquaporins (AQP) are channel-forming integral membrane
proteins that allow the movement of water through cell mem-
branes [1]. These selective channels belong to the broad super-
family of the major intrinsic protein (MIP) transmembrane
channels, which are found in eubacteria, archaea, fungi, proto-
zoa, plants, and animals. To date, 13 diﬀerent aquaporins
(AQP0-12) have been found in diverse human tissues. The im-
paired function of aquaporins has been associated with several
human diseases, such as congenital cataracts or nephrogenic
diabetes insipidus [1]. Aquaporins assemble as tetramers in
the plasma membrane, with each monomer containing a chan-
nel [1]. The aquaporin family can be divided into two sub-Abbreviations: AQP, aquaporin; BAT, brown adipose tissue; FABP,
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free fatty acids; GK, glycerol kinase; HSL, hormone-sensitive lipase;
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CK, phosphoenolpyruvate carboxykinase; PPARc, peroxisome prolif-
erator-activated receptor c; TG, triglycerides; TZD, thiazolidinediones;
WAT, white adipose tissue
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aquaporins (pure water channels) and aquaglyceroporins
(channels permeated by water and small solutes, such as gly-
cerol). Aquaporin-7 (AQP7), together with AQP3, AQP9
and AQP10, belongs to the aquaglyceroporin subfamily [2].
The human AQP7 gene, mapped to chromosome 9p13, was
cloned from adipose tissue in 1997 (originally named AQPap)
[3,4]. Despite its initial description as an adipose-speciﬁc gly-
cerol channel, this pore has been shown to be also expressed
in kidney, testis, ovary, heart, gastrointestinal tract, and skeletal
muscle [5–10]. AQP7 facilitates the secretion of glycerol from
adipocytes. Glycerol constitutes a key metabolite in the control
of fat accumulation (as the carbon backbone of triglycerides
(TG)) and glucose metabolism (as the major substrate for hepa-
tic gluconeogenesis during fasting) [11,12]. Since mice lacking
the AQP7 gene develop adult-onset obesity and type 2 diabetes
mellitus, it was proposed that the glycerol channel AQP7 plays a
pivotal role in adipose tissue enlargement and function as well as
in glucose homeostasis [13]. The expression of AQP7 is posi-
tively up-regulated by fasting and peroxisome proliferator-acti-
vated receptor c (PPARc) agonists [14–17], whereas refeeding,
insulin, dexamethasone and tumour necrosis factor-a (TNF-a)
suppress the expression of this glycerol channel [14,18]. Thus,
the regulation of AQP7 expression in adipose tissue might be
one of the determining factors for the control of fat accumula-
tion and whole body glucose homeostasis [19,20].2. Control of adipogenesis and adipocyte function
Adipocyte diﬀerentiation is a highly controlled process,
where the expression of adipose-speciﬁc genes is crucial for
determining phenotypic characteristics of adipocytes. The
transcription factors that regulate this process include PPARc,
CCAAT enhancer binding protein (C/EBP) and sterol-regula-
tory element binding proteins (SREBP) [14]. The human AQP7
gene promoter presents binding sites for these transcription
factors, suggesting that this glycerol channel is involved in adi-
pocyte diﬀerentiation. In this sense, it has been shown that the
expression of AQP7 in undiﬀerentiated 3T3-L1 preadipocytes
is almost negligible, while AQP7 becomes markedly expressed
during the late adipogenesis in a process mediated by PPARc,
the master adipogenic transcription factor [12,15].
In diﬀerentiated adipocytes, TG synthesis and hydrolysis are
stimulated according to the energetic status [20]. During peri-
ods of caloric excess, adipocytes take up free fatty acids (FFA),blished by Elsevier B.V. All rights reserved.
Fig. 1. Role of AQP7 in adipocyte formation and function. During fasting or exercise, triglycerides are hydrolysed to glycerol and FFA and released
to the bloodstream. Glycerol is secreted from the adipose tissue through AQP7, a glycerol channel mainly expressed in adipocytes during late
adipogenesis.
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biosynthesis, glycerol-3-phosphate, proceeds from three meta-
bolic sources: (i) glucose; (ii) glycerol derived from lipolysis,
which is phosphorylated by glycerol kinase (GK); or (iii)
pyruvate, which is converted to glycerol by the activity of
phosphoenolpyruvate carboxykinase (PEPCK) (Fig. 1). In
circumstances of negative energy balance, such as fasting
or exercise, TG are hydrolysed to glycerol and FFA by the
hormone-sensitive lipase (HSL) and released into the blood-
stream. Several membrane proteins, including fatty acid bind-
ing protein (FABP), fatty acid translocase (FAT, CD36) or
fatty acid transporter protein (FATP), facilitate the FFA
transport across the membrane [14]. About 30–40% of FFA
are recycled back to TG in white adipose tissue (WAT) [11].
However, the recycling of FFA also occurs in other peripheral
tissues, such as liver, skeletal muscle, heart, pancreas or brown
adipose tissue (BAT), where FFA are oxidized or re-esteriﬁed
to TG. On the other hand, AQP7 appears to be one of the
main channels for glycerol release from adipocytes, a process
that contributes to the regulation of fat accumulation. In this
sense, it has been shown that adipocytes of AQP7-deﬁcient
mice exhibit a higher intracellular glycerol content than those
of wild type (WT) mice [13]. A recent study has reported that
glycerol induces conformational changes and enzymatic activ-
ity of GK, which is a key enzyme in the conversion of glycerolto glycerol-3-phosphate [21]. Thus, a defective glycerol exit re-
sults in intracellular glycerol accumulation, which induces the
enzymatic activity of GK. The consequent increase in glycerol-
3-phosphate concentrations promotes the biosynthesis of TG,
resulting in a progressive adipocyte hypertrophy [22].
The expression of AQP7 and the molecules that contribute to
the eﬄux of FFA from adipocytes are tightly regulated by the
nutritional state. Fasting increases the levels of AQP7 and
FATP1 (a FFA transport protein) in adipose tissue, whereas
refeeding suppresses the expression of these proteins [14,15].
In addition, insulin decreases AQP7 and FATP1 expression
in WAT, since their gene promoters present a negative insulin
response element (IRE) [14,15]. Therefore, a coordinated regu-
lation of the expression levels of AQP7 and FATP1 by insulin is
programmed to work as an eﬃcient mechanism for supplying
energy in accordance with nutritional needs.3. Glucose homeostasis
Glycerol is one of the major factors that determine plasma
glucose [11]. During fasting and post-absorptive states, hepatic
glucose output is the main source of plasma glucose in rodents,
and plasma glycerol becomes the major substrate for hepatic
gluconeogenesis [11,12]. Adipose tissue constitutes the most
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ciﬁc glycerol channel, represents a gateway for the delivery
of fat-derived glycerol into plasma. This plasma glycerol is
introduced into hepatocytes by the liver-speciﬁc aquaglycero-
porin AQP9, where it is converted into glycerol-3-phosphate
by the enzymatic activity of GK for de novo synthesis of glu-
cose (Fig. 2) [23]. After feeding, plasma concentrations of insu-
lin increase and this hormone inhibits the expression of AQP7
in WAT and of AQP9 in liver through the negative IRE in the
promoter regions of these genes. Interestingly, the insulin-
resistant obese db/db mice exhibit increased expression levels
of the fat-speciﬁc AQP7 and the liver-speciﬁc AQP9, despite
their hyperinsulinemia [23]. The increase of these aquaglycero-
porins in the setting of insulin resistance may be caused by
impaired IRS-1-mediated insulin signalling in adipocytes
and reduced IRS-2-induced insulin signalling in hepatocytes
[14,23]. Taken together, under physiological conditions, insu-
lin-mediated regulation of AQP7 and AQP9 may account for
the increase or decrease of glycerol release from fat and gluco-
neogenesis in liver, in order to regulate the glucose production
depending on the nutritional state. However, in the context
of insulin resistance, the overexpression of AQP7 and AQP9
leads to an increase of plasma glycerol and hepatic glucose
production associated with elevated circulating glycerol con-Fig. 2. AQP7 and AQP9 function in glucose homeostasis. Insulin constitut
hepatocytes, through the negative IRE in their gene promoters. Plasma insu
therefore, AQP7 and AQP9 expression in fat cells and liver, respectively, inc
setting of insulin resistance, AQP7 and AQP9 are overexpressed, despite th
glycerol use for hepatic gluconeogenesis increase, enhancing the hyperglycemcentrations, a circumstance that further aggravates the hyper-
glycemia.
Thiazolidinediones (TZD), e.g. pioglitazone and rosig-
litazone, are oral antidiabetic agents that increase insulin-
sensitivity via the stimulation of PPARc. Pioglitazone and
rosiglitazone administration to rodents has been shown to
increase the expression of AQP7 in adipose tissue [15,17].
Despite the upregulation of AQP7 by TZDs, glycerol release
from adipocytes is not increased. This apparent paradox could
be understood when Lee et al. [17] reported that TZD also
increase GK activity, favouring the recycling of glycerol for
TG synthesis instead of stimulating the release of glycerol to
bloodstream. The authors further observed that hepatic
AQP9 expression was not aﬀected by TZD treatment, proba-
bly due to a lower expression of PPARc in the liver. Therefore,
the undesirable increase of adipose AQP7 expression in insu-
lin-resistant states, which might lead to elevated plasma gly-
cerol levels and, consequently, hepatic gluconeogenesis, can
be overcome through an increased glycerol recycling in adipo-
cytes using TZDs.
Cathecolamines induce lipolysis, increasing the release of
FFA and glycerol from fat into the bloodstream [18]. This pro-
cess has been suggested as one of the mechanisms by which
cathecolamines may impair insulin sensitivity. Interestingly,es a repressor of the expression of AQP7 in adipocytes and AQP9 in
lin concentrations change in accordance to the nutritional state and,
rease or decrease in relation to the nutritional needs. However, in the
e hyperinsulinemia. Consequently, glycerol output from fat cells and
ia.
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AQP7 expression through activation of Gs-proteins and aden-
ylyl cyclase in accordance with the classical induction of b-
adrenergic receptors [18]. Although the eﬀect of isoproterenol
on AQP7 expression has been observed in cultured 3T3-L1
adipocytes, the ﬁnding suggests that, under physiological cir-
cumstances, increased cAMP levels induced by cathecolamines
may not only enhance lipolysis but also repress AQP7 expres-
sion in adipocytes, thereby restricting to some extent glycerol
release from adipocytes. In an insulin-resistant state, the bal-
ance between stimulation of lipolysis and downregulation of
the AQP7 gene induced by cathecolamines might be impaired.
However, observations made in isolated adipocytes or cell cul-
tures do not necessarily reﬂect the processes taking place in
whole-body regulation. In this sense, additional work is needed
to better clarify the true impact of adrenergic stimulation.4. Aquaporin-7 deﬁciency leads to obesity and insulin resistance
The suppression of the AQP7 gene in mice is associated with
adult-onset obesity [13,22,24]. The latest insights into AQP7
function regarding fat accumulation regulation stem from
two diﬀerent strains of mice, C57BL/6N and CD1, lacking
the protein [13,22,24]. AQP7 knockout (KO) mice backcrossedFig. 3. AQP7 deletion eﬀect on lipid and glucose homeostasis. The loss of gly
in intracellular glycerol, favouring the new biosynthesis of triglycerides. In ad
impaired IRS-1-mediated insulin signalling, and its inhibition of hepatic
Consequently, AQP7-deﬁcient mice exhibit a progressive fat accumulation
insulin resistance. Striped arrows indicate inhibition; solid arrows indicate sinto the C57BL/6N genetic background exhibit similar body
weights to WT animals until 12 weeks of age, when AQP7-null
mice start to accumulate fat and become heavier, despite having
the same food intake as WT mice [13,24]. The other line of
AQP7 KO, generated in CD1 mice by Hara-Chikuma et al.,
did not put on excess weight but exhibited a signiﬁcantly in-
creased whole body fat accumulation [22]. The diﬀerences in
body weight of the two lines of mice may be ascribed to the di-
verse genetic backgrounds [13]. Why do AQP7-deﬁcient mice
become obese? A plausible mechanism is related to the fact of
a reduced energy expenditure in AQP7-KO mice since their
body temperature is lower than that of WT mice after 20 weeks
of age [13]. A reduction in triglyceride/FFA cycling (Fig. 3) and
the associated heat production may underlie the lower body
temperature observed in AQP7 knockout mice [11,12]. Alterna-
tively, since the defence of the thermal set point is controlled in
the hypothalamus, hypothermia would be also consistent with
a central eﬀect of AQP7 deﬁciency [12]. Nonetheless, additional
studies are needed to disentangle the exact mechanisms under-
lying the eﬀect of AQP7 deﬁciency on body temperature. To
date, the main cause for the increased weight gain in adult
AQP7-null mice constitutes the excessive accumulation of tri-
glycerides in subcutaneous and visceral fat pads [13,22,24]. This
excess of fat mass is not the result of either a decreased lipolysis
or an increased adipogenesis, since the activity of HSL, a keycerol release from adipocytes of AQP7-deﬁcient mice causes an increase
dition, insulin fails to exert its antilipolytic action in adipocytes, due to
gluconeogenesis, as a result of low IRS-2-associated PI3K activity.
and metabolic alterations, such as elevated FFA, hyperglycemia and
timulation.
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and C/EBPa, two important transcription factors involved in
adipogenesis, are not aﬀected by AQP7 deletion. The major
reason for the enlargement of adipose tissue in AQP7-deﬁcient
mice is the progressive hypertrophy of adipocytes, character-
ised by larger sized lipid droplets [13,22]. AQP7 disruption
results in a reduced glycerol permeability of the plasma mem-
brane of adipocytes and, hence, in an intracellular glycerol
accumulation. The increased enzymatic activity of GK in
adipocytes from AQP7-null mice accelerates TG synthesis,
leading to a progressive fat accumulation (Fig. 3).
AQP7 deletion in mice is accompanied by an age-related
development of severe insulin resistance [13]. Young AQP7-
KO mice (10-week-old) present decreased fasting plasma gly-
cerol and glucose concentrations. Glycerol secretion from
adipocytes is not completely abolished in AQP7-KO mice, sug-
gesting that other mechanisms, such as simple diﬀusion and/or
other glycerol channels, are also probably involved in glycerol
secretion [24,25]. The fasting hypoglycemia of these young
mice may be related to a low glycerol transport to the liver to-
gether with an ineﬃcient gluconeogenesis, despite an increased
PEPCK activity, a key liver enzyme that converts glucose from
pyruvate and/or glycerol, as well as due to the eﬀect of coun-
terregulatory hormones, like glucagon and corticosterone.
On the other hand, fasting plasma insulin concentrations and
glucose tolerance tests of young AQP7-KO mice are similar
to age-matched WT mice. Insulin signalling also appears to
be functional in young AQP7-null mice, since insulin-stimu-
lated phosphorylation of Akt in WAT, liver and muscle is sim-
ilar to that of WT mice [24]. However, adult AQP7-KO mice
(20-week-old) show increased fasting plasma glucose and insu-
lin concentrations, disturbed insulin-mediated suppression of
plasma glucose and impaired glucose tolerance [13]. Why do
AQP7 deﬁcient mice become insulin-resistant? Insulin signal-
ling is impaired in insulin-sensitive tissues of adult AQP7 deﬁ-
cient mice [13]. Insulin stimulation of IRS-1-associated PI3K
activity in WAT and muscle, and IRS-2 associated PI3K activ-
ity in liver and muscle, are markedly decreased in AQP7 KO
mice (Fig. 3). Moreover, insulin-stimulated phosphorylation
of Akt in WAT, liver and muscle is signiﬁcantly lower in
AQP7 null mice. In addition, young AQP7 KO mice (8-
week-old) fed a high fat diet or sucrose during 4 weeks showed
higher plasma insulin and glucose concentrations, as well as
impaired insulin-mediated suppression of plasma glucose and
impaired glucose tolerance. Thus, AQP7-deﬁcient mice are
also vulnerable to diet-induced obesity and insulin resistance
[13]. Together, these results suggest that deletion of AQP7
leads to whole-body insulin resistance associated with adult-
onset obesity.5. Concluding remarks
The functional importance of AQP7 in mammalian patho-
physiology has been extensively studied by analysing the
phenotype of transgenic knockout mice lacking this aquaglyc-
eroporin. Although the expression and regulation of AQP7 in
liver and adipose tissue have been extensively addressed, its
expression in skeletal muscle, a key metabolic organ in glucose
and lipid metabolism, merits further research. AQP7 has been
shown to be expressed on the surface of human type 1 and type2 ﬁbres as well as of murine type 2 muscle ﬁbres [10]. In this
context, eﬀorts aimed at elucidating the contribution of skele-
tal muscle AQP7 expression both under physiological circum-
stances as well as in relation to potential changes related to
diﬀerent insulin resistance states deserve preferential consider-
ation. In addition, the tissue-speciﬁc invalidation of AQP7 in
adipose tissue, liver and skeletal muscle may prove useful to
decipher the relative impact of this glycerol channel to glucose
and energy homeostasis in well-known insulin-sensitive or-
gans.
Until now, results of AQP7 expression in humans are scarce.
Therefore, abusive extrapolation of rodent data to humans
should be avoided, until the contribution of AQP7 to the path-
ophysiology of obesity and insulin resistance is speciﬁcally
addressed in these patients as well as in normal-weight, normo-
glycaemic individuals. For instance, only a single human case
of homozygous mutation in the coding region of the AQP7
gene has been reported up to date [16]. Contrary to what
was observed in AQP7 deﬁcient mice, this subject was neither
obese nor diabetic. The only apparent consequence of this
mutation was an impaired glycerol increase in response to
exercise. Moreover, a number of results in humans are limited
to mRNA determinations without functional studies on intact
adipocytes. In lean and obese individuals eating similar high-
fat diets, a decreased expression of AQP7 was observed in sub-
cutaneous adipose tissue [26]. From a clinical point of view, it
would be interesting to discern whether the presence of insulin
resistance modiﬁes AQP7 gene expression in WAT of lean and
obese subjects. Apparently, the coordinated regulation of
fat-speciﬁc AQP7 and liver-speciﬁc AQP9 expression might
be disrupted in human obesity and type 2 diabetes mellitus.
However, additional studies related to gene expression and
protein stability are needed to better establish a ﬁrm mechanis-
tic basis for the involvement of AQP7 in the etiopathogenesis
of these metabolic disorders in humans. A deeper understand-
ing of the regulation of AQP7 together with that of AQP9 in
key metabolic organs might be useful to design drugs speciﬁ-
cally targeting plasma membrane channels aimed at obesity
and/or type 2 diabetes mellitus control.
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